Literature DB >> 8165536

Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: a cooperative study of the Keio Bile Duct Cancer Study Group.

Y Sugiura1, S Nakamura, S Iida, Y Hosoda, S Ikeuchi, S Mori, A Sugioka, T Tsuzuki.   

Abstract

BACKGROUND: It is necessary to elucidate whether extensive resection of the bile ducts combined with liver resection is a feasible and valid procedure for cancer of the main hepatic duct junction.
METHODS: Based on a multi-institutional study, resectability rate, operative mortality, long-term survival, and factors contributory to long-term survival were investigated.
RESULTS: Between January 1973 and December 1991, a total of 158 patients with this cancer were admitted to Keio University Hospital and six affiliated institutions. Eighty-three (53%) of the 158 patients underwent resection, with seven (8.4%) postoperative deaths. The operations were performed by seven surgeons who were in charge of liver surgery at each respective institution. The 5-year actuarial survival rate of the 83 patients who underwent resection was 20%. Twelve patients survived more than 5 years, and these patients underwent curative resection. Three of the 12 patients were doing well after 10 years. Procedures of liver resection were right trisegmentectomy in two patients and left lobectomy with resection of the right portal vein in one.
CONCLUSIONS: It is clear that cancer of the main hepatic duct junction has become a curable disease. The operation is a valid procedure that can be widely practiced by competent surgeons.

Entities:  

Mesh:

Year:  1994        PMID: 8165536

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  32 in total

1.  Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience.

Authors:  J I Tsao; Y Nimura; J Kamiya; N Hayakawa; S Kondo; M Nagino; M Miyachi; M Kanai; K Uesaka; K Oda; R L Rossi; J W Braasch; J M Dugan
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

2.  Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter?

Authors:  Anthony T Ruys; Fiebo J W Ten Kate; Olivier R Busch; Marc R Engelbrecht; Dirk J Gouma; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2011-09-26       Impact factor: 3.647

3.  Bile duct surgery in the treatment of hepatobiliary and gallbladder malignancies: effects of hepatic and vascular resection on outcomes.

Authors:  Perry Shen; Nora Fino; Edward A Levine; Pamela Eversole; Clancy Clark
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

4.  Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma.

Authors:  Noriaki Sagawa; Satoshi Kondo; Toshiaki Morikawa; Shunichi Okushiba; Hiroyuki Katoh
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  "Anatomic" right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma.

Authors:  Masato Nagino; Junichi Kamiya; Toshiyuki Arai; Hideki Nishio; Tomoki Ebata; Yuji Nimura
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

6.  Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer.

Authors:  Tatsuharu Yamada; Toshiyuki Arai; Masato Nagino; Koji Oda; Junichi Shoda; Hiroshi Suzuki; Yuichi Sugiyama; Yuji Nimura
Journal:  Langenbecks Arch Surg       Date:  2005-06-17       Impact factor: 3.445

7.  Preoperative evaluation with T-staging system for hilar cholangiocarcinoma.

Authors:  Ru-Fu Chen; Zhi-Hua Li; Jia-Jia Zhou; Jie Wang; Ji-Sheng Chen; Qing Lin; Qi-Bing Tang; Ning-Fu Peng; Zhi-Peng Jiang; Quan-Bo Zhou
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

8.  Retrohepatic inferior vena cava reconstruction with saphenous vein patch in advanced stage cholangiocarcinoma.

Authors:  Abuzer Dirican; Mustafa Özsoy; Bora Barut; Volkan İnce; Mustafa Ateş; Sezai Yılmaz
Journal:  Ulus Cerrahi Derg       Date:  2014-09-01

9.  Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate.

Authors:  Yasuji Seyama; Keiichi Kubota; Keiji Sano; Tamaki Noie; Tadatoshi Takayama; Tomoo Kosuge; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

10.  Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection?

Authors:  Kevin Tri Nguyen; Jennifer Steel; Tsafrir Vanounou; Allan Tsung; J Wallis Marsh; David A Geller; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2009-09-23       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.